| Pyroptosis is a critical inflammatory pathway in the placenta from early onset preeclampsia and in human trophoblasts exposed to hypoxia and endoplasmic reticulum stressors SB Cheng, A Nakashima, WJ Huber, S Davis, S Banerjee, Z Huang, ... Cell death & disease 10 (12), 927, 2019 | 191 | 2019 |
| Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo MR Hassler, AA Turanov, JF Alterman, RA Haraszti, AH Coles, MF Osborn, ... Nucleic acids research 46 (5), 2185-2196, 2018 | 162 | 2018 |
| Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways MF Osborn, AH Coles, A Biscans, RA Haraszti, L Roux, S Davis, S Ly, ... Nucleic acids research 47 (3), 1070-1081, 2019 | 120 | 2019 |
| The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy A Biscans, J Caiazzi, S Davis, N McHugh, J Sousa, A Khvorova Nucleic Acids Research 48 (14), 7665-7680, 2020 | 58 | 2020 |
| Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1 SM Davis, VN Hariharan, A Lo, AA Turanov, D Echeverria, J Sousa, ... Molecular Therapy-Nucleic Acids 29, 135-149, 2022 | 32 | 2022 |
| Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection VN Hariharan, M Shin, CW Chang, D O’Reilly, A Biscans, K Yamada, ... Proceedings of the National Academy of Sciences 120 (11), e2219523120, 2023 | 22 | 2023 |
| Lung gene expression in a rhesus allergic asthma model correlates with physiologic parameters of disease and exhibits common and distinct pathways with human asthma and a mouse … AR Abbas, JK Jackman, SL Bullens, SM Davis, DF Choy, G Fedorowicz, ... The American journal of pathology 179 (4), 1667-1680, 2011 | 20 | 2011 |
| Lung effects of inhaled corticosteroids in a rhesus monkey model of childhood asthma CG Plopper, JP Joad, LA Miller, ES Schelegle, MV Fanucchi, ... Clinical & Experimental Allergy 42 (7), 1104-1118, 2012 | 16 | 2012 |
| 2′-O-Methyl at 20-mer guide strand 3′ termini may negatively affect target silencing activity of fully chemically modified siRNA SM Davis, J Sousa, L Vangjeli, MR Hassler, D Echeverria, E Knox, ... Molecular Therapy-Nucleic Acids 21, 266-277, 2020 | 14 | 2020 |
| Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity K Yamada, S Hildebrand, SM Davis, R Miller, F Conroy, E Sapp, J Caiazzi, ... Nucleic Acids Research 49 (21), 12069-12088, 2021 | 11 | 2021 |
| O-methyl rich fully stabilized oligonucleotides A Khvorova, J Alterman, S Davis, A Turanov US Patent 11,279,930, 2022 | 8 | 2022 |
| O-methyl rich fully stabilized oligonucleotides A Khvorova, J Alterman, S Davis, A Turanov US Patent App. 16/999,759, 2021 | 8 | 2021 |
| O-methyl rich fully stabilized oligonucleotides A Khvorova, J Alterman, S Davis, A Turanov US Patent App. 17/580,269, 2022 | 7 | 2022 |
| Oligonucleotides for SARS-CoV-2 modulation A Khvorova, J Watts, Z Kennedy, A Biscans, BM da Cruz Godinho, ... US Patent 12,077,758, 2024 | 4 | 2024 |
| Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders A Khvorova, VN Hariharan, S Davis, A Biscans, A Karumanchi US Patent 11,702,659, 2023 | 4 | 2023 |
| Oligonucleotides for app modulation A Khvorova, C FERGUSON, S Davis | 3 | 2023 |
| Oligonucleotides for mapt modulation A Khvorova, C Ferguson, S Davis, K Monopoli US Patent App. 17/204,480, 2021 | 3 | 2021 |
| Guidelines for designing therapeutic siRNAs SM Davis UMass Chan Medical School, 2023 | 1 | 2023 |
| Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders A Khvorova, VN Hariharan, S Davis, A Biscans, A Karumanchi US Patent App. 18/321,971, 2024 | | 2024 |
| Oligonucleotides for app modulation A Khvorova, C Ferguson, S Davis US Patent App. 18/120,030, 2023 | | 2023 |
